Primary small cell carcinoma of vagina: report of two cases

Jingni Zhang¹, Yi Luo¹, Rui Yuan¹,²

¹Department of Obstetrics and Gynecology, the First Affiliated Hospital of Chongqing Medical University, 400016 Chongqing, China
²Correspondence: Yru96@hospital.cqmu.edu.cn (Rui Yuan)

DOI: 10.31083/j.ejg04206189

Background: Primary small cell carcinoma of vagina (SCCV) is highly malignant and rare. Only 39 patients with this malignancy can be found in a search of the PubMed and MEDLINE database, and most of them died within 12 months of diagnosis. Cases: We report two patients with primary vaginal small cell carcinomas. Their tumors show similar histologic and ultrastructural neuroepithelial elements. Both of them underwent radical surgery, received different adjuvant therapy, and had different outcomes. One is without recurrence 36 months after surgery and the other recurred within 2 months of completing treatment. Conclusion: Although surgery for the treatment of early-stage disease is suggested, surgery followed by chemotheraphy and radiation may be superior to surgery alone. Receiving chemotherapy and radiotherapy as soon as possible after surgery may improve patient prognosis.

Keywords
Small cell carcinoma; Immunohistochemical staining; Chemotheraphy; Survival time

1. Introduction

Over 95% of primary small cell carcinomas (SCC) occur in the lungs, and a small number of primary SCC originate in the genital tract. SCC accounts for only 1%–2% of all gynecological malignant tumors [1]. It occurs most frequently in cervix and rarely in the vagina. Most of the patients die within 1 year of diagnosis [1]. After searching the PubMed and MEDLINE database, we found only 39 reported cases [2–30] of primary vaginal small cell carcinoma (SCCV) and the current managements have usually resulted in poor outcomes, however, due to the rarity of the lesion, there is no standard guideline of treatment.

2. Case 1

A 51-year-old woman complaining of vaginal discharge was admitted to the hospital in December 2017. She had no significant medical history. Thin-prep cytology test of cervix was benign and HPV DNA assay was negative. The special tumor marker of SCC, neuron specific enolase (NSE), and other tumor markers such as squamous cell carcinoma antigen were almost normal. The physical examination showed a neoplasm about 2 cm in the posterior fornix of vagina. Hematoxylin-eosin (HE) staining of biopsy tissue was consistent with malignancy (Fig. 1). The immunohistochemical stains demonstrated positivity for chromogranin A (CgA) and synaptophysin (Syn) (Fig. 2). The MRI film of the pelvis showed that the lymph nodes were not enlarged. PET/CT scans were negative for metastatic diseases.

Subsequently she underwent radical hysterectomy with partial vaginectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy. Gross examination of the specimen found the greatest tumor width was 2 cm with invasion of deep soft tissue. Microscopy showed the tumor deeply infiltrated all layers of the vaginal wall but didn’t extend beyond tunica adventitia to paravaginal tissue, and cancer thrombus was found in vessels. Lymph nodes and vaginal margins were negative. Immunohistochemical analysis was consistent with the earlier results. Finally, clinical stage I (T1N0M0) SCCV was confirmed. Postoperatively she received etopside a dose of 100 mg/m² and cisplatin at a dose of 60 mg/m² every 3 weeks for 6 courses, followed by external beam radiotherapy to the pelvis, 45 Gy in 25 fractions. Eight months after initial visits, her MRI of the pelvis demonstrated no evidence of local recurrence or distant metastases. She has remained clinically free of disease of 36 months since surgery.

3. Case 2

An asymptomatic 44-year-old woman was found to have a 2 × 2 cm, right-sided, firm vaginal polypoid mass in October 2019. She had no significant medical or surgical history. Neuron specific enolase (NSE) was normal. A biopsy was consistent with a small cell malignant neoplasm. A MRI of the pelvis confirmed the presence of a vaginal mass arising from the right side of the vagina and a lymph node near the right side of upper vagina (Fig. 3). CT scan of lungs and Papanicolaou test were negative.

She received radical hysterectomy with partial vaginectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy and paravaginal lymph node resection. Pathological examination showed tumor deeply infiltrating the vaginal wall with lymph nodes and vaginal margins negative. Immunohistochemical analysis showed positivity for CD56, CgA and Syn (Fig. 2). The disease was designated as clinical stage I (T1N0M0) SCCV. The patient was offered postoperatively concurrent chemoradiation. After receiving chemotherapy with etopside (100 mg/m²) and nedaplatin (80 mg/m²)
After 4 courses, she declined further therapy. Two months later, PET/CT scans showed recurrence with local lesion and metastatic lesion in the liver. She underwent pelvic tumor cytoreductive surgery in July 2020, followed by chemotherapy with paclitaxel and nedaplatin. Her treatment was complicated by anemia resulting in death 14 months after her cancer diagnosis.

4. Discussion
The first case of SCCV was reported by Scully et al. [30] in 1984. SCCV is extremely aggressive and rarely reported with only 39 patients found in our search of the PubMed and MEDLINE database. SCCV may be asymptomatic with a lesion in vagina but usually manifest with postmenopausal bleeding or vaginal discharge. They may also manifest with symptoms due to metastasis, such as abdominal pain, and hemoptysis. Though it has been well known that SCC of cervix are associated with human papilloma virus (HPV) especially HPV 16 and 18 infections, there is not definitive evidence to show that SCCV is related to HPV infection, because only one case [3] of SCCV reported HPV status.

The histologic appearance of SCC under light microscopy is small cells with round or oat-shaped nucleus, scant cytoplasm and deeply stained nucleoli to differentiate SCC from other tumors appearing as small blue cells such as lymphoma and sarcoma, immunohistochemical analysis is often performed. The positivity of neuroendocrine markers CD56, neuron-specific enolase (NSE), chromogranin A (CgA) and synaptophysin (Syn) are significant for diagnosis. As reported by Bing et al. [14], 7 cases were subjected to NSE and Syn, and all showed positivity. CgA was performed in 8 cases with 7 positive and 1 negative. The negativity of lymphocytotoxic antibody helps to exclude lymphoma. Thyroid transcription factor 1 (TTF-1) is a sensitive marker for SCC of pulmonary origin, but the expression in urinary bladder, uterine cervix and vagina has also been reported [14, 31], in other words, it is not specific enough to distinguish primary SCCV and SCC metastatic from the lung. Though the HE and immunohistochemical staining patterns of SCC in different parts of genital tract are similar [32], SCC metastatic from cervix or lung must be excluded before SCCV diagnosed. Thus clinical evaluation combined with radiographic examination and ThinPrep cytologic test (TCT) is necessary to determine whether there are cervical or pulmonary lesions.

Currently most studies about SCCV are case reports and there is no standard guideline for treatment. With the neuroendocrine phenotype, the management strategies for SCC of female genital tract are often adopted from strategies for SCC of the lung [32]. A clinical document about SCC of genital tract released by Society of Gynaecologic Oncology in 2011 suggested that the approach to managing SCC of the cervix could be extrapolated to SCCV. Radical excision was suggested in early-stage disease, and chemo-radiotherapy with platinum and etoposide is suitable for advanced cases [1]. Considering the different clinical outcomes of we reported two patients, we believe that supplementary radiotherapy and chemotherapy after surgery may be necessary for patients with early-stage disease. To date, 33 [2–5, 7–9, 11–15, 17–28] of the 39 patients with SCCV reported in the English literature are available for clinical and pathological
| Literature                        | NO. Pa | Age, y | TNM stage | Primary therapy                                                                 | Response | Outcome | Survival, mo |
|----------------------------------|--------|--------|------------|---------------------------------------------------------------------------------|----------|---------|--------------|
| Present study                    | 1      | 51     | I: T1N0M0  | Sequential: radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy; CT with EP; RT | CR       | AWND    | At least 36  |
|                                  | 1      | 44     | I: T1N0M0  | Sequential: radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy; CT with EP | Recurrence with local and metastatic lesion | Died    | 14           |
| Kombathula et al. in 2019 [2]    | 1      | 65     | III: T2N1M0 | Sequential: neoadjuvant CT; C-CR; adjuvant CT                                    | CR       | AWND    | At least 22  |
| Kostamo et al. in 2018 [4]       | 1      | 32     | II: T2N0M0  | Sequential: radical hysterectomy with partial vaginectomy, left oopexy, right salpingo-oophorectomy and right pelvic lymphadenectomy; CT with topotecan, paclitaxel, and bevacizumab; RT | CR       | Died    | 34           |
| Haykal et al. in 2018 [3]        | 1      | 56     | I: T1N0M0  | Sequential: CT with EP; C-CR with cisplatin/taxol                              | Ongoing treatment | Alive  | At least 3   |
| Yan WX et al. in 2016 [5]        | 1      | 43     | IV: TXN1M1 | C-CR with cisplatin and paclitaxel                                             | CR       | AWND    | At least 21  |
| Tamura et al. in 2013 [7]        | 1      | 81     | I: T1N0M0  | RT                                                                               | CR       | AWND    | At least 20  |
| Khurana et al. in 2013 [9]       | 1      | 37     | II: T2N0M0  | Sequential: total vaginectomy and pelvic lymphadenectomy; CR with EP; RT       | CR       | AWND    | At least 12  |
| Oliveira et al. in 2013 [8]      | 1      | 43     | II: T2N0M0  | Sequential: CT with EP; RT                                                      | CR       | AWND    | At least 5   |
| Weberpals et al. in 2008 [11]    | 1      | 61     | IV: TXN1M1 | CT with EP                                                                       | PR       | Died    | 8            |
| Coleman et al. in 2006 [12]      | 1      | 67     | IV: T3N1M1 | Sequential: RT; CT with EP                                                       | Recurrence with a metastatic lesion | AWD     | At least 8   |
| Petru et al. in 2004 [13]        | 1      | 50     | II: T2N0M0  | Sequential: anterior exenteration,pelvic lymphadenectomy; CT with EP and epirubicin | No description | Died    | 11           |
| Zhanqyong Bing et al. in 2004 [14]| 3      | 74     | IV: T3N1M1 | Palliative CRT with CDDP and etoposide                                          | PR       | Died    | 4            |
|                                  |        | 55     | III: T2N1M0 | Surgery: radical vaginovulvectomy and bilateral node dissection                | Apparently CR but with distant failure | Died    | 4            |
|                                  |        | 38     | IV: T4NXM0 | C-CR                                                                             | Ongoing therapy | Alive  | At least 5   |
| Kaminiski et al. in 2003 [15]    | 1      | 69     | I: T1N0M0  | C-CR with EP                                                                     | PR       | Died    | 13           |
| Hayashi et al. in 2000 [17]      | 1      | 51     | I: T1NXM0  | CT with cyclophosphamide, pirarubicin and cisplatin                             | CR       | AWND    | At least 41  |
| Elsahel et al. in 2000 [18]      | 1      | 57     | III: T3N0M0 | C-CR with carboplatin and etoposide                                             | CR       | Died    | 14           |
| Mirhashemi et al. in 1998 [19]   | 1      | 32     | III: T3N0M0 | Sequential: CT with EP; RT                                                      | CR       | AWND    | At least 6   |
| Colleran et al. in 1997 [20]     | 1      | 59     | II: T2N0M0  | C-CR with EP                                                                     | CP       | Died    | 26           |
| Miliauskas and Leong in 1992 [23]| 1      | 78     | III: TXN1M0 | Surgery: modified right hemivaginovulvectomy and right side inguinal node dissection | CR       | Died    | 10           |
| Prasad et al. in 1992 [21]       | 1      | 34     | II: T2N0M0  | Sequential: vaginectomy and bilateral inguinal node dissection; CT with EP; RT | CR       | Died    | 6            |
Table 1. Continued.

| Literature                     | NO. Pa | Age, y | TNM stage | Primary therapy                                | Response | Outcome | Survival, mo |
|--------------------------------|--------|--------|-----------|------------------------------------------------|----------|---------|--------------|
| Joseph et al. in 1992 [22]     | 1      | 65     | I: T1N0M0 | Sequential: CT with vincristine, doxorubicin and cyclophosphamide; RT | CR       | AWND    | At least 24  |
| Rusthoven and Daya in 1990 [24]| 1      | 63     | II: T2N0M0| Sequential: CT; RT                             | Local lesion progressed during CT | Died    | Nearly 8     |
| Chafe in 1989 [25]             | 2      | 78     | II: T2N0M0| RT                                             | CR       | Died    | 15           |
|                               |        | 74     | II: T2N0M0| RT                                             | CR       | Died    | 11           |
| Hopkins et al. in 1989 [26]    | 3      | 41     | II: T2N0M0| RT                                             | Died     | 29      |
|                               |        | 68     | IV: TXNXM1| RT and CT with adriamycin and cytoxan          | Died     | 5       |
|                               |        | 73     | IV: TXNXM1| CT with cisplatinum and dichloromethotrexate   | Died     | 9       |
| Fukushima et al. in 1986 [28] | 1      | 32     | II: T2N0M0| RT                                             | CR       | Died    | 12           |
| Peters et al. in 1985 [29]     | 5      | 61 (mean)|          | No details                                     | 1 patient obtaining CR | Died    | 12 (mean)    |
| Jain et al. in 2016 [6]        | 2      |        |           | No clinical details                            |          |         |              |
| Bhalodia et al. in 2011 [10]   | 1      | 50     |           | No clinical details                            |          |         |              |
| Ng et al. in 2003 [16]         | 1      | 70     | IV: T4N0M0| CT                                             | No description |         |              |
| Ulrich et al. in 1986 [27]     | 1      |        |           | No clinical details                            |          |         |              |
| Scully et al. in 1984 [30]     | 1      |        |           | No clinical details                            |          |         |              |

NO. Pa, number of patient; CT, chemotherapy; EP, etopside and cisplatin; RT, radiation; CRT, chemo-radiotherapy; C-CR, Concurrent chemo-radiation; PR, partial response; and CR, complete response; AWND, alive with no disease; AWD, alive with disease.

The stage was based on American Joint Committee on Cancer stage in 2002.
information. The clinical details of patients including 6 in stage I, 13 in stage II, 7 in stage III, and 7 in stage IV were showed in Table 1 (Ref. [1, 3–30]). The age of all patients ranges from 32 years to 81 years and the median is 59 years. The median survival time was 12 months, ranging from 4 months to 41 months. Four patients (1 in stage I and 3 in stage II) underwent surgery and postoperative chemoradiotherapy. When therapy finished, all of them showed a clinical complete response (CR) and were alive without disease progression when reported. A patient in stage II received chemotherapy following surgery and two patients in stage III underwent surgery alone, all of them died within 1 year. Interestingly, the median survival time of the patients receiving radiation alone (1 in stage I and 4 in stage II) was 15 months and 80% of them achieved CR. Chemo-radiotherapy was administered to 14 patients (3 in stage I, 3 in stage II, 3 in stage III and 5 in stage IV). 7 of them achieved CR and 2 achieved partial response (PR). Disease progressed in 2 of them and outcome of 3 patients was unknown. The median survival time of patients treated by chemo-radiotherapy was 8 months. Three patients underwent chemotherapy alone and one of the them reported by Hayashi et al. [17] was alive for more than 41 months with no evidence of disease, and other of them die in 8 months and 9 months of diagnose, respectively.

5. Conclusions

Since radiation may be effective in local control, chemoradiotherapy may be superior to chemotherapy alone in advanced cases, and surgery followed by chemo-radiotherapy may be also superior to surgery alone. Receiving chemotherapy and radiotherapy as soon as possible after surgery may improve prognosis.

Author contributions

JZ, YL and RY conceived and designed the review. JZ was involved in the collection and collation of references. YL collected and assembled the data presented in Table 1. JZ and YL wrote the manuscript. All authors approved the final manuscript.

Ethics approval and consent to participate

The Ethics Committee of the First Affiliated Hospital of Chongqing Medical University approved the study. Approval number is 2020–655. All subjects gave their informed consent for inclusion before they participated in the study.

Acknowledgment

We would like to express my gratitude to all those who helped me during the writing of this manuscript.

Funding

This research received no external funding.

Conflict of interest

The authors declare no conflict of interest.

References

[1] Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecologic Oncology. 2011; 122: 190–198.

[2] Kombathula SH, Rapole PS, Prem SS, Badhe B. Primary small cell carcinoma of the vagina: a rare instance of prolonged survival. BMJ Case Reports. 2019; 12: e227100.

[3] Haykal T, Pandit T, Bachuwa G, Danish R. Stage I small cell cancer of the vagina. BJM Case Reports. 2018; 2018: bcr2018225294.

[4] Kostamo K, Pearth M, McKenzie N, Holloman C, Carlan SJ, Ge L, et al. Novel treatment of small-cell neuroendocrine of the vagina. Case Reports in Oncological Medicine. 2018; 2018: 1–3.

[5] Yan WX, Jia XJ, Chen YB, Zhao ZX, Liu XL, Yang JZ, et al. Primary small cell carcinoma of the vagina with pulmonary metastasis: a case report. European Journal of Gynaecological Oncology. 2016; 37: 120–132.

[6] Jaz V, Sekhon R, Giri S, Bora RR, Batra K, Bajracharya A, et al. Role of radical surgery in early stages of vaginal cancer—our experience. International Journal of Gynecologic Cancer. 2016; 26: 1176–1181.

[7] Tamura R, Yokoyama Y, Kobayashi A, Osawa Y, Shigeto T, Futagami M, et al. A case of small cell carcinoma of the vagina. Rare Tumors 2013; 5: e58.

[8] Oliveira R, Bocoli MC, Saldanha JC, Murta EFC, Nomelini RS. Primary small cell carcinoma of the vagina. Case Reports in Obstetrics and Gynecology. 2013; 2013: 827037.

[9] Khurana A, Gupta G, Gupta M, Kaur M. Primary neuroendocrine carcinoma of the vagina with coexistent atypical vaginal adenosis: a rare entity. Journal of Cancer Research and Therapeutics. 2013; 9: 328–330.

[10] Bhalodia JN, Kapapura DV, Parekh MN. Primary small cell neuroendocrine carcinoma of vagina: a rare case report. Pathology Research International. 2011; 2011: 306921.

[11] Weberpals J, Djordjevic B, Khalifa M, Oza A. A rare case of ectopic adrenocorticotropic hormone syndrome in small cell carcinoma of the vagina: a case report. Journal of Lower Genital Tract Disease. 2008; 12: 140–145.

[12] Coleman NM, Smith-Zagone MJ, Tanyi J, Anderson ML, Coleman RL, Dyson SW, et al. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. American Journal of Surgical Pathology. 2006; 30: 405–410.

[13] Petru E, Pasterek C, Reich O, Oberrain A, Winter R, Breiteneker G. Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Archives of Gynecology and Obstetrics. 2005; 271: 316–319.

[14] Bing Z, Levine L, Lucci JA, Hatch SS, Eltorky MA. Primary small cell neuroendocrine carcinoma of the vagina: a clinicopathologic study. Archives of Pathology & Laboratory Medicine. 2004; 128: 857–862.

[15] Kaminski JM, Anderson PR, Han AC, Mitra RK, Rosenblum NG, Edelson MI. Primary small cell carcinoma of the vagina. Gynecologic Oncology. 2003; 88: 451–455.

[16] Ng WK, Cheung LK, Li AS, Tse SK, Pang SW, Chow JC. Thin-layer cytology findings of small cell carcinoma of the lower female genital tract. Review of three cases with molecular analysis. Acta Cytologica. 2003; 47: 56–64.

[17] Hayashi M, Mori Y, Takanari Y, Hoshimoto K, Ohkura T. Primary small cell neuroendocrine carcinoma of the vagina. Marked effect of combination chemotherapy: a case report. Oncology. 2000; 58: 300–304.

[18] Elsahel H, Bydder S, Cassidy B, Thompson J. Small cell carcinoma of the vagina. Australasian Radiology. 2000; 44: 336–337.
Mirhashemi R, Kratz A, Weir MM, Molpus KL, Goodman AK. Vaginal small cell carcinoma mimicking a Bartholin’s gland abscess: a case report. Gynecologic Oncology. 1998; 68: 297–300.

Colleran KM, Burge MR, Crooks LA, Dorin RI. Small cell carcinoma of the vagina causing Cushing’s syndrome by ectopic production and secretion of ACTH: a case report. Gynecologic Oncology. 1997; 65: 526–529.

Prasad CJ, Ray JA, Kessler S. Primary small cell carcinoma of the vagina arising in a background of atypical adenosis. Cancer. 1992; 70: 2484–2487.

Joseph RE, Enghardt MH, Doering DL, Brown BF, Shafer DW, Raval HB. Small cell neuroendocrine carcinoma of the vagina. Cancer. 1992; 70: 784–789.

Miliauskas JR, Leong AS. Small cell (neuroendocrine) carcinoma of the vagina. Histopathology. 1992; 21: 371–374.

Rusthoven JJ, Daya D. Small-cell carcinoma of the vagina. A clinicopathologic study. Archives of Pathology & Laboratory Medicine. 1990; 114: 728–731.

Chafe W. Neuroepithelial small cell carcinoma of the vagina. Cancer. 1989; 64: 1948–1951.

Hopkins MP, Kumar NB, Lichter AS, Peters WA, Morley GW. Small cell carcinoma of the vagina with neuroendocrine features. A report of three cases. Journal of Reproductive Medicine. 1989; 34: 486–491.

Ulich TR, Liao SY, Layfield L, Romansky S, Cheng L, Lewin KJ. Endocrine and tumor differentiation markers in poorly differentiated small-cell carcinoids of the cervix and vagina. Archives of Pathology & Laboratory Medicine. 1986; 110: 1054–1057.

Fukushima M, Twigg LB, Okagaki T. Mixed intestinal adenocarcinoma-argentaffin carcinoma of the vagina. Gynecologic Oncology. 1986; 23: 387–394.

Peters WA, Kumar NB, Morley GW. Carcinoma of the vagina. Factors influencing treatment outcome. Cancer. 1985; 55: 892–897.

Scully RE, Aguirre P, DeLellis RA. Argyrophilia, serotonin, and peptide hormones in the female genital tract and its tumors. International Journal of Gynecological Pathology. 1984; 3: 51–70.

Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. American Journal of Surgical Pathology. 2000; 24: 1217–1223.

Patibandla JR, Fehniger JE, Levine DA, Jelinic P. Small cell cancers of the female genital tract: molecular and clinical aspects. Gynecologic Oncology. 2018; 149: 420–427.